- Home
- QNCX vs CHPT Comparison
QNCX vs CHPT Comparison
Compare QNCX & CHPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | QNCX | CHPT |
|---|---|---|
| Founded | 2012 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Industrial Specialties |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 167.0M | 155.2M |
| IPO Year | 2019 | N/A |
Fundamental Metrics
Financial Performance| Metric | QNCX | CHPT |
|---|---|---|
| Price | $0.18 | $5.87 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 3 | 12 |
| Target Price | $10.00 | ★ $12.68 |
| AVG Volume (30 Days) | ★ 142.3M | 573.5K |
| Earning Date | 03-23-2026 | 03-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $403,793,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $7.60 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.13 | $5.53 |
| 52 Week High | $4.55 | $17.78 |
Technical Indicators
Market Signals| Indicator | QNCX | CHPT |
|---|---|---|
| Relative Strength Index (RSI) | 27.90 | 41.53 |
| Support Level | $0.13 | $5.67 |
| Resistance Level | $0.98 | $6.76 |
| Average True Range (ATR) | 0.32 | 0.37 |
| MACD | -0.03 | 0.04 |
| Stochastic Oscillator | 1.72 | 32.11 |
Price Performance
Historical ComparisonAbout QNCX Quince Therapeutics Inc.
Quince Therapeutics Inc is preclinical stage biopharmaceutical company focused on advancing precision therapeutics for debilitating and rare diseases. The company discovered a broad bone-targeting drug platform designed to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease to promote rapid healing with fewer off-target safety concerns compared to non-targeted therapeutics. Company pipeline includes Ataxia-Telangiectasia(EryDex), Duchenne Muscular Dystrophy, New Indications and Program Expansion Potential.
About CHPT ChargePoint Holdings Inc.
ChargePoint Holdings Inc designs, develops, and markets networked electric vehicle charging system infrastructure and cloud-based services that enable consumers to locate, reserve, and authenticate EV charging. The company's hardware product lineup includes solutions across home, commercial, and fast-charging applications. ChargePoint derives the majority of its revenue from the United States.